Nirmatrelvir/ritonavir and molnuipiravir in the treatment of mild/moderate COVID-19: results of a real-life study

Ivan Gentile, Riccardo Scotto, Nicola Schiano Moriello, Biagio Pinchera, Riccardo Villari, Emilia Trucillo, Luigi Ametrano, Ludovica Fusco, Giuseppe Castaldo, Antonio Riccardo Buonomo, Federico II COVID team
doi: https://doi.org/10.1101/2022.08.23.22278585

Article Information

doi 
https://doi.org/10.1101/2022.08.23.22278585
History 
  • August 25, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Ivan Gentile1,
  2. Riccardo Scotto1,*,
  3. Nicola Schiano Moriello1,
  4. Biagio Pinchera1,
  5. Riccardo Villari1,
  6. Emilia Trucillo1,
  7. Luigi Ametrano1,
  8. Ludovica Fusco1,
  9. Giuseppe Castaldo2,3,
  10. Antonio Riccardo Buonomo1,
  11. Federico II COVID team
  1. 1Department of Clinical medicine and Surgery - University of Naples Federico II – Naples Italy
  2. 2Department of Molecular Medicine and Medical Biotechnologies - University of Naples Federico II – Naples Italy
  3. 3CEINGE - Advanced Biotechnologies - Naples Italy
  1. ↵*Corresponding author; email: ri.scotto{at}gmail.com
    Back to top
    Posted August 25, 2022.
    Download PDF
    Data/Code
    Email
    Nirmatrelvir/ritonavir and molnuipiravir in the treatment of mild/moderate COVID-19: results of a real-life study
    Ivan Gentile, Riccardo Scotto, Nicola Schiano Moriello, Biagio Pinchera, Riccardo Villari, Emilia Trucillo, Luigi Ametrano, Ludovica Fusco, Giuseppe Castaldo, Antonio Riccardo Buonomo, Federico II COVID team
    medRxiv 2022.08.23.22278585; doi: https://doi.org/10.1101/2022.08.23.22278585
    Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools

    Subject Area